Ollin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedMC
Mubadala Capital
Activity from announced rounds
Activity in this selectionSeries B
Mubadala Capital is the investment manager whose official portfolio includes Ollin, Alloy, Juvena and Crusoe.
Recorded funding activity
Ollin develops retinal-disease antibodies. Alloy supplies discovery platforms and services, while Crusoe develops computing infrastructure. The manager remains separate from Mubadala Investment Company; the Precision Neuroscience relation stays in draft.
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $363.5M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionJuvena Therapeutics
Develops regenerative biologics to restore tissue function
$33.5MSeries B
Role not disclosed